Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas

Autor: Marek Grabiec, Dariusz Grzanka, Pawel Sadlecki
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Adult
0301 basic medicine
Oncology
Neuroblastoma RAS viral oncogene homolog
medicine.medical_specialty
Article Subject
endocrine system diseases
Clinical Biochemistry
Real-Time Polymerase Chain Reaction
GTP Phosphohydrolases
03 medical and health sciences
0302 clinical medicine
Obstetrics and gynaecology
Internal medicine
Ovarian carcinoma
Biomarkers
Tumor
Genetics
Humans
Medicine
Cystadenocarcinoma
Molecular Biology
Aged
Aged
80 and over
Ovarian Neoplasms
lcsh:R5-920
Oncogene
business.industry
Biochemistry (medical)
Membrane Proteins
Cancer
Sequence Analysis
DNA
General Medicine
Middle Aged
medicine.disease
Cystadenocarcinoma
Serous
Serous fluid
030104 developmental biology
Molecular Diagnostic Techniques
030220 oncology & carcinogenesis
Mutation
Ovarian carcinomas
Female
business
lcsh:Medicine (General)
Research Article
Zdroj: Disease Markers, Vol 2018 (2018)
Disease Markers
ISSN: 1875-8630
0278-0240
Popis: The Idylla NRAS Mutation Test, performed on the Biocartis Idylla system, is an in vitro diagnostic tool for the qualitative assessment of 18 NRAS mutations in codons 12, 13, 59, 61, 117, and 146. Low-grade serous ovarian cancer (LGSC) represents less than 10% of all serous ovarian carcinomas. LGSCs are believed to arise from preexisting cystadenomas or serous borderline tumors (SBOTs) that eventually progress to an invasive carcinoma. The molecular analysis of cancer-causing mutations and the development of targeted biological therapies constitute a milestone in the diagnosis and therapy of ovarian malignancies. According to some authors, NRAS may be an important oncogene for the progression of SBOT to a frankly invasive disease. The primary aim of this study was to verify if a fully integrated, real-time PCR-based Idylla system can be used for the rapid determination of the NRAS mutation status in patients with serous borderline ovarian tumors and low-grade serous ovarian carcinomas. The study included tissue specimens from 12 patients with histopathologically verified ovarian masses, operated on at the Department of Obstetrics and Gynecology, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz (Poland), between January 2009 and June 2012. The mean age of the study patients was 52.5 years (range 27–80 years). NRAS mutation in codon 13 (G13D, p.Gly13Asp; nucleotide: c.38G>A) was found in one patient, a woman with low-grade serous ovarian carcinoma. To the best of our knowledge, our experiment was the first published study using the novel Idylla NRAS Mutation Test for the evaluation of ovarian tumors in a clinical setting. The Idylla platform is an interesting ancillary first-line rapid and fully automated instrument to detect NRAS mutations in SBOTs and LGSCs. However, the clinical usefulness of this method still needs to be verified in larger groups of cancer patients.
Databáze: OpenAIRE
Externí odkaz: